2 Matching Annotations
  1. Aug 2022
  2. www.medrxiv.org www.medrxiv.org
    https://medrxiv.org/cgi/content/10.1101/2022.03.08.22271822
    1
    1. jackiekrauss 29 Aug 2022

      Thuluva, S., Paradkar, V., Turaga, K., Gunneri, S., Yerroju, V., Mogulla, R., Kyasani, M., Manoharan, S. K., Medigeshi, G., Singh, J., Shaman, H., Singh, C., & Rao, A. V. (2022). Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies (p. 2022.03.08.22271822). medRxiv. https://doi.org/10.1101/2022.03.08.22271822

      is:preprint lang:en COVID-19 vaccine Corbevax vaccine safety immunogenicity optimum formulation RBD protein sub-unit vaccine adverse event cellular response safety concern
    Visit annotations in context

    Tags

    Annotators

    URL

    medrxiv.org/content/10.1101/2022.03.08.22271822v1
  3. www.livemint.com www.livemint.com
    Has Mudra scheme been successful?
    1
    1. jackiekrauss 29 Aug 2022

      Banerjee, P. (2022, February 13). Biological E seeks EUA for its Corbevax vaccine for 12-18 yrs age group. Mint. https://www.livemint.com/news/india/biological-e-seeks-eua-for-its-corbevax-vaccine-for-12-18-yrs-age-group-11644746753338.html

      is:news lang:en EUA COVID-19 Corbevax vaccine 12-18 year-olds DCGI India RBD protein sub-unit vaccine vaccine emergency use authorization clinical study
    Visit annotations in context

    Tags

    Annotators

    URL

    livemint.com/economy/the-simmering-debate-over-poverty-rate-11683142431495.html